InnovaDerma PLC provided earnings guidance for the second half and full year ending June 30, 2018. The Board continues to expect the second half year to outperform the first half significantly, however revenue growth for the year will now be less than anticipated at the time of the interim results. This has been mainly driven by lower than expected orders placed by Superdrug for Skinny Tan despite the brand's continued growth. The Group expects revenues to be substantially higher than last year. The profit before tax is now expected to be similar to fiscal year 2017 due to the significant investment made across the business over the last six months.